This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 Oct 2013

ZOSTAVAX (Zoster Vaccine Live) Awarded Prix Galien USA

Merck, known as MSD outside the US and Canada, has announced that ZOSTAVAX (Zoster Vaccine Live), the company's vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product.

“Merck is honored to have been chosen as a recipient of this prestigious award,” said Dr Roger M. Perlmutter, president, Merck Research Laboratories. “This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring ZOSTAVAX to market.”

The Prix Galien Award recognises the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognised award, the Prix Galien was founded in France in 1969 by French pharmacist Roland Mehl and is considered the highest accolade for pharmaceutical research and development.
This latest award for ZOSTAVAX is Merck's sixth Prix Galien USA award in 7 years. The company was previously recognized for VICTRELIS (2012), ROTATEQ (2010), ISENTRESS (2008), and JANUVIA and GARDASIL (2007). In total, around the world, Merck has won the Prix Galien more than 30 times, making Merck one of the two most-awarded companies of all time.

Related News